July 29, 2016 / 12:48 IST
Religare's research report on Torrent Pharma
TRP’s Q1FY17 earnings missed our/consensus estimates by 9-12% due to weak domestic growth and price erosion in gAbilify. However, the Brazilian business rebounded strongly with a 21% YoY growth – the highest in last 2-3 years. Also, the US base business (ex-gAbilify) posted low double-digit growth despite price erosion (5-7%). Normalisation in India sales and improved EU and US businesses led by higher Dahej capacity should partly offset the erosion in gAbilify revenues. Maintain HOLD; Mar’17 TP Rs 1,560.
For all recommendations, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!